teaser
The FDA has granted priority review to a supplemental New Drug Application for bortezomib (Velcade®) as a treatment for patients with newly diagnosed multiple myeloma.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
The submission is based in part on data from the phase III VISTA(1) study, which compared a combination of bortezomib, melphalan and prednisone (VcMP) with the standard regimen of melphalan and prednisone (MP) in 682 patients with newly diagnosed disease, unsuitable for stem cell transplantation.
In the UK, bortezomib is licensed for use in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation.
